T1	Participants 129 151	standard-risk patients
T2	Participants 222 240	high-risk patients
T3	Participants 387 414	standard-risk (SR) patients
T4	Participants 499 566	PATIENTS AND METHODS SR patients (localized tumors, volume <100 mL)
T5	Participants 846 891	HR patients (volume >or=100 mL or metastases)
T6	Participants 1161 1173	647 patients
T7	Participants 1198 1212	79 SR patients
T8	Participants 1236 1250	76 SR patients
T9	Participants 1274 1280	240 HR
T10	Participants 1308 1323	252 HR patients
T11	Participants 1391 1399	SR group
T12	Participants 1837 1864	patients without metastases
T13	Participants 1907 1928	those with metastases
T14	Participants 2052 2063	SR patients
T15	Participants 2111 2122	HR patients
